United Therapeutics Corporation (UTHR) Guidance & Earnings Results
On 2026-02-25 United Therapeutics Corporation raised guidance: "Durable double-digit revenue growth…" — from its own filing, as read by EquiReason.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
UTHRUnited Therapeutics CorporationFollow UTHR — free
—
Price chart with a free account
- Market cap
- 25.2B
- P/E TTM
- 21.0
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 4 Nov, in 11 days
What management guided
each earnings 8-K · figures checked against the filing text| Release | Direction | What they said |
|---|---|---|
| 25 Feb 26 | Raised | Durable double-digit revenue growth expected · full year |
| 30 Jul 25 | Reaffirmed | Management expects continued double-digit revenue growth for Tyvaso and total revenues; no numerical guidance provided. |
United Therapeutics Corporation — questions
- What guidance did United Therapeutics Corporation give?
- On 2026-02-25: "Durable double-digit revenue growth expected"
- When does United Therapeutics Corporation report earnings?
- United Therapeutics Corporation's next earnings report is expected on 2026-11-04.
Every figure on this page comes from United Therapeutics Corporation's own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.